TOKYO, Japan (AFP) – Experts hailed full data Wednesday showing a new drug can slow cognitive decline in Alzheimer’s patients, but warned improvements were comparatively small and the treatment can have serious side effects. Preliminary data from a trial of lecanemab was released in September and found it slowed cognitive decline by 27 percent across an 18-month period. The complete trial data, published in the New England Journal of Medicine, fleshes out those findings but also […]